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Abstract
Introduction. Laxatives are commonly used to treat
opioid-induced constipation, the commonest and
most bothersome complication of opioids.
However, laxatives have a nonspecific action and
do not target underlying mechanisms of opioid-
induced constipation; their use is associated with
abdominal symptoms that negatively impact quality
of life.
Objective. To assess the effects of laxatives in pa-
tients taking opioids for chronic pain.
Methods. One hundred ninety-eight UK patients
who had taken opioid analgesics for at least one
month completed a cross-sectional online or tele-
phone survey. Questions addressed their pain con-
dition, medication, and laxative use (including
efficacy and side effects). The survey also as-
sessed bowel function using the Bowel Function
Index.
Results. Since starting their current opioid, 134 of
184 patients (73%) had used laxatives at some point
and 122 (91%) of these were currently taking them.
The most common laxatives were osmotics and
stimulants. Laxative side effects were reported in
75%, most commonly gas, bloating/fullness, and a
sudden urge to defecate. Side effects were more
common in patients less than 40 years of age.
Approximately half of patients said laxatives inter-
fered with work and social activities, and one-fifth
needed an overnight hospital stay because of their
pain condition and/or constipation. Laxatives did
not improve the symptoms of constipation, as as-
sessed by the Bowel Function Index. Constipation
was not related to opioid strength, dose of opioid,
or number of laxatives taken.
VC 2016 American Academy of Pain Medicine.
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Conclusions. Use of laxatives to treat opioid-induced
constipation is often ineffective and associated with
side effects. Instead of relieving the burden of opioid-
induced constipation, laxative use is associated with
a negative impact.
Key Words. Opioid; Opioid-Induced Constipation;
Laxatives; Chronic Pain; Survey; Bowel Function
Index
Introduction
Opioids have been important in pain management for a
number of years. According to the World Health
Organization’s three-step analgesic ladder, weak opi-
oids (e.g., codeine, dihydrocodeine, tramadol) should be
used for moderate pain (at Step 2) and strong opioids
(e.g., oxycodone, morphine) for severe pain (at Step 3)
[1]. Despite being originally developed for cancer pain,
this stepwise approach has been extended for use in
chronic noncancer pain.
Opioids are known to cause a number of gastrointestinal
(GI) side effects that are collectively termed opioid-
induced bowel dysfunction (OIBD). OIBD is characterized
by hard, dry stools, straining, incomplete evacuation,
bloating, abdominal distension, and increased gastric
reflux [2]. The most common symptom of OIBD is opioid-
induced constipation (OIC) [3,4]. Opioids cause constipa-
tion by binding to m-opioid receptors in the GI tract,
which reduces GI secretions and peristaltic activity and
increases fluid reabsorption [5]. The result is hard, dry
stools that pass slowly through the gut. OIC is dose-
dependent, and, unlike other GI symptoms, patients
rarely develop tolerance to the constipating effects of
opioids, so OIC does not resolve over time [6].
As well as being the most common symptom of OIBD,
constipation is the most bothersome and debilitating
[3,7,8]. Some patients will reduce or miss their dose of opi-
oid medication to avoid OIC [7,8,9], preferring to tolerate
the pain than experience constipation symptoms [10]. OIC
negatively impacts patients’ quality of life, no matter how
advanced their disease or condition [11]. It also carries a
significant economic burden in terms of both direct costs
(patients may use additional health care resources) [12,13]
and indirect costs (patients’ ability to work may be af-
fected, leading to both absenteeism and presenteeism)
[13]. Studies carried out in Sweden and the United States
showed that total health costs are significantly higher for
patients with OIC than for those without [14–17].
Laxatives are commonly used to treat OIC. However,
they do not target the underlying mechanism of OIC, as
they do not impact binding to m-opioid receptors in the
GI tract, and many patients will not have their constipa-
tion resolved with this therapeutic approach. In one sur-
vey of patients with chronic noncancer pain, 54% of
those treated for OIC with laxatives did not achieve the
desired effect even half of the time [2]. In another survey,
96% of patients taking one laxative and 38% taking two
laxatives had an inadequate response to treatment [9].
The multinational Prevalence, Severity, and Impact of
Opioid-Induced Bowel Dysfunction (PROBE1) survey as-
sessed OIBD in 322 patients who were receiving opioids
for chronic pain and taking laxatives [7]. Eighty-one per-
cent of patients reported that they experienced consti-
pation despite taking laxatives, and more than half said
that constipation had a “moderate-to-great” or “great”
impact on their quality of life. Patients also reported a
number of other symptoms, such as bloating and gas,
which negatively impacted their quality of life. As all pa-
tients were taking laxatives, it may have been possible
that this reflected the side effects of laxatives as well as
the symptoms of OIBD. We therefore carried out a sur-
vey to specifically look at laxative use in patients receiv-
ing opioids, focusing on: 1) the types of laxatives used
to treat OIC, 2) the effect of laxatives on symptoms of
constipation, 3) the side effects associated with laxa-
tives, and 4) the impact of laxatives on quality of life.
Methods
This was a cross-sectional survey carried out in the
United Kingdom between May 2013 and October 2014.
Patients were recruited via social media, pharmacies,
and advertisements in newspapers and on patient web-
sites. Patients with any pain condition (including back
pain, arthritis, cancer, headache and nerve pain) who
had been taking Step 2 or 3 oral opioid medication
(e.g., codeine, dihydrocodeine, oxycodone, morphine,
or tramadol) for at least one month were eligible to take
part. Back pain could include failed back surgery,
osteoporosis, and nonspecific pain. At screening, any
patients who had not been taking opioids for at least
one month were excluded from completing the full sur-
vey and no further details were collected.
Patients completed the survey online or over the tele-
phone. The survey included questions on patients’ pain
condition, opioid medication, laxative use, bowel move-
ments, and contact with health care professionals.
Patients who said they were using laxatives were asked
to select side effects they had experienced from a list of
common symptoms. Those who reported at least one
side effect were then asked how much laxatives inter-
fered with their work and social activities on a five-point
scale, where 1¼ all of the time and 5¼ none of the
time. Patients were also asked about any other meas-
ures they had taken to try and ease their constipation.
Bowel movements were assessed using the Bowel
Function Index (BFI) [18]. Patients rated ease of defeca-
tion, feeling of incomplete bowel evacuation, and per-
sonal judgement of constipation on a scale of 0–100,
where a lower score indicated better bowel function
[18]. Their total BFI score was calculated as the mean
of these three scores. Normal bowel function was
defined as a BFI score of 28.8 or lower [19]. The BFI is
a validated tool [20,21] that has been endorsed by the
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American Academy of Pain Medicine Foundation and
the American Gastroenterological Association for as-
sessment of OIC [22,23].
The study was submitted to the National Research
Ethics Centre, who confirmed that it would not require
formal approval.
Data were analyzed descriptively. For categorical vari-
ables, the number and percentage falling into each cat-
egory were reported. For continuous variables, the mean,
standard deviation, median, interquartile range (IQR), and
range were reported. Statistical analyses were performed
using SAS v9.2.
Results
Patient Characteristics
In total, 362 patients were screened and 198 were eligible
to participate. Their median age was 50.2 years; 81%
were over age 40 years. Most (85%) were female, and
just over half (52%) reported they were unable to work
owing to illness or disability (Table 1). Most (65%) were re-
cruited via advertisements on the internet (Table 1).
Back pain, nerve pain, and arthritis were the most com-
mon indications for opioid use (Table 2). The most com-
mon types of back pain were sciatica, arthritis of the
spine, and slipped disc. Codeine and codeine combin-
ations were the most common currently prescribed opi-
oids (Table 3). The mean (6SD) number of opioids
prescribed was 1.5 (60.6), and 84 patients (42%) re-
ported that they were currently prescribed two or more
opioids; of these, 40 patients were taking a combination
of weak and strong opioids. One hundred fifty-four pa-
tients (154/183, 84%) had been on their current opioid
for at least six months; 82 of 188 patients (44%) re-
ported that codeine and codeine combinations were
their longest-prescribed opioid.
Constipation and Laxative Use
More than three-quarters of patients reported that they
had no history of constipation before taking opioids (142/
185, 77%). Eighty-eight patients (88/198, 44%) said that
their general practitioner had discussed constipation with
them, and most patients said they had made lifestyle
changes to try and help with their symptoms: 142 (72%)
reported altering their diet (e.g., eating more fiber and
increasing water intake), and 40 (20%) reported starting
exercise (e.g., walking or swimming) or physical therapy.
However, it was not clear whether patients made these
lifestyle changes as a result of GP advice. More than
half of patients (110/198, 56%) said that their GP had
offered no advice on dealing with their constipation.
Since starting their current opioid, 134 of 184 patients
(73%) had taken a laxative at some point; of these, 122
(91%) were currently taking them. The mean (6SD)
number of laxatives currently used was 1.36 (60.81).
Twenty-eight (23%) of the 122 patients currently taking
laxatives were taking two or more, and 74 (61%) had
been taking them for more than six months. The most
common laxatives used were osmotics and stimulants
(Table 4). In general, laxatives had been prescribed by a
health care professional; over-the-counter (OTC) use
was low, with the exception of stimulants: 50 (37%) of
the 134 patients who had used laxatives since being
prescribed their current opioid said that they had used
OTC stimulants (most often senna).
Side Effects and Impact on Quality of Life
Three-quarters of patients currently taking opioids re-
ported side effects with their use (91/122, 75%). The
most common side effects were gas, bloating or full-
ness, and sudden urge to defecate (Table 5). Side ef-
fects were more common in younger patients: 83% of
Table 1 Patient demographics
Analysis population (N¼ 198) N (%)
Age, y
N (missing) 194 (4)
Mean (6SD) 49.36 (11.60)
Median (IQR) 50.22 (43.46–56.53)
Min, max 18.48, 79.74
Age category
N (missing) 194 (4)
<40 y, N (%) 37 (19.1)
>40 y, N (%) 157 (80.9)
Sex
N (missing) 198 (0)
Male, N (%) 29 (14.6)
Female, N (%) 169 (85.4)
Current employment
status, N (%)
N (missing) 181 (17)
Employed/in
education, N (%)
62 (34.3)
Retired, N (%) 19 (10.5)
Unable to work
owing to illness/
disability, N (%)
94 (51.9)
Other, N (%) 6 (3.3)
Method of recruitment
to study, N (%)
N (missing) 196 (2)
Internet advert 128 (65.3)
Newspaper article 5 (2.6)
Pain clinic 6 (3.1)
Patient organization
website
10 (5.1)
Pharmacist leaflet 4 (2.0)
Other 43 (21.9)
IQR ¼ interquartile range.
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patients (19/23) younger than age 40 years reported at
least one side effect, compared with 73% (69/95) older
than age 40 years. The most common side effects in
younger patients were gas, sudden urge to defecate,
and false alarm (Table 5). There appeared to be no as-
sociation between side effects and opioid strength or
occupational status (data not shown).
Laxatives were considered to interfere “at least a little of
the time” with work for 58 of the 122 patients currently
taking them (48%) and with social activities for 62
(51%). Sixteen patients (13%) reported that laxatives
substantially interfered with social activities; this was
most commonly attributed to gas, bloating, urge/fecal
incontinence, and false alarm.
Almost half of the patients (95/198, 48%) reported that
they had used other interventions to help with their con-
stipation since starting their current laxative. These
included herbal remedies, massage, and use of ene-
mas. Forty-two patients (21%) said that they removed
hard or dry stools by hand. Almost half of patients who
had experienced frequent constipation before starting
opioids, 20 of 43 (47%), used manual evacuation meth-
ods (colon irrigation therapy, enemas, massage, and
Table 2 Pain conditions
Pain type
Number of patients (%)
(N¼198)
Back pain 130 (65.7)
Osteoporosis 12 (6.1)
Slipped disc 34 (17.2)
Arthritis of the spine 44 (22.2)
Failed back surgery 20 (10.1)
Sciatica 62 (31.3)
Nonspecific back pain 27 (13.6)
Other 45 (22.7)
Not sure 7 (3.5)
Arthritis 81 (40.9)
Osteoarthritis 48 (24.2)
Rheumatoid arthritis 17 (8.6)
Other 6 (3.0)
Not sure 16 (8.1)
Cancer 3 (1.5)
Headache 45 (22.7)
Nerve pain 95 (48.0)
Ongoing pain after accident 33 (16.7)
Ongoing pain after surgery 43 (21.7)
Other 44 (22.2)
Not sure 2 (1.0)
Patients could record more than one type of back pain or
arthritis.
Table 3 Currently prescribed opioid medications
Number of patients (%)
(N¼198)
Prescribed opioid medication
Codeine and codeine
combinations
102 (51.5)
Dihydrocodeine 28 (14.1)
Hydromorphone 2 (1.0)
Methadone 3 (1.5)
Morphine 65 (32.8)
Oxycodone 18 (9.1)
Tapentadol 1 (0.5)
Tramadol and tramadol
combinations
78 (39.4)
Strength of prescribed opioid
Strong only 42 (21.2)
Weak only 116 (58.6)
Combination of weak and strong 40 (20.2)
Patients could record more than one opioid.
Table 4 Types of laxatives used
Laxative type
Number of patients (%)
(N¼134)
Osmotic
Ever prescribed 62 (46.3)
Ever OTC 7 (5.2)
Currently taking 53 (39.6)
Stimulant
Ever prescribed 46 (34.3)
Ever OTC 50 (37.3)
Currently taking 56 (41.8)
Bulk forming
Ever prescribed 12 (9.0)
Ever OTC 8 (6.0)
Currently taking 16 (11.9)
Softener
Ever prescribed 8 (6.0)
Ever OTC 1 (0.7)
Currently taking 9 (6.7)
Enema
Ever prescribed 7 (5.2)
Ever OTC 3 (2.2)
Currently taking 5 (3.7)
Suppository
Ever prescribed 3 (2.2)
Ever OTC 5 (3.7)
Currently taking 5 (3.7)
Other
Ever prescribed 5 (3.7)
Ever OTC 13 (9.7)
Currently taking 9 (6.7)
Patients could record more than one type of laxative.
OTC ¼ over the counter.
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removal by hand), compared with 42 of 142 (30%) who
were not previously constipated.
Health Care Contacts
Most patients (169/198, 85%) reported that they had
seen either a GP or a practice nurse about their pain
condition and/or constipation since starting current
treatment. One hundred and eight patients (55%) re-
ported that they had visited their GP more than five
times about their pain condition. For constipation alone,
the corresponding figure was 15 patients (8%). Some
patients had also had health care contacts in a second-
ary care setting, including 39 (20%) who had required
an overnight stay in the hospital (Table 6).
Bowel Function Index
In total, 185 patients completed the BFI questionnaire.
Their mean (6SD) total score was 52.1 (631.5), and 75%
had a total score higher than 28.8 (i.e., were consti-
pated). Patients’ BFI scores according to laxative use,
opioid strength, and number of laxatives taken are shown
in Table 7. Laxative use did not appear to improve the
symptoms of constipation: patients who had used laxa-
tives (N¼134) since starting their current opioid had a
mean (6SD) BFI score of 58.2 (630.2), compared with
36.5 (629.0) for patients who had not used laxatives
(N¼ 50). BFI scores were not related to opioid strength,
with a mean difference of less than two points in the total
score between patients taking weak and strong opioids.
Taking more laxatives did not improve BFI scores; in fact,
the mean total score and the proportion of patients with a
total score higher than 28.8 increased with increasing
number of laxatives used.
Forty-three patients (43/185, 23%) reported that they
had experienced frequent constipation before starting
their current opioid, suggesting that they may have
been particularly prone to the condition. A post hoc
analysis revealed that the BFI scores in these individuals
did not differ from those of the total study cohort: their
mean (6SD) total score was 51.8 (631.4), and 32
(74%) had a BFI score higher than 28.8.
Opioid Exposure
A post hoc analysis showed that patients were taking a
median daily morphine equivalent dose of 40 mg (range ¼
4.8–580 mg) (Table 8). The descriptive data suggested
there was no relationship between increasing daily mor-
phine equivalent dose and higher BFI scores (although
this was not formally tested). Patients’ median daily
morphine equivalent doses were similar, regardless of
whether they had experienced frequent constipation be-
fore starting on opioids or not (Table 8). The descriptive
data also suggested there was also no clear relationship
between daily morphine equivalent dose and laxative use
(again, this was not formally tested). Patients who had
never taken a laxative tended to be taking lower morphine
equivalent doses than those who had used a laxative at
some point since starting their current opioid (Table 8).
Discussion
The results of our survey confirm that constipation is
very common among patients receiving oral opioids to
Table 5 Side effects experienced by laxative
users
N (%)
All patients Age < 40 y Age 40þ y
(N¼ 122) (N¼23) (N¼95)
None 31 (25.4) 4 (17.4) 26 (27.4)
Unpleasant
taste/texture
21 (17.2) 7 (30.4) 13 (13.7)
Nausea 22 (18.0) 6 (26.1) 15 (15.8)
Bloating or fullness 37 (30.3) 5 (21.7) 31 (32.6)
Gas 52 (42.6) 13 (56.5) 39 (41.1)
Dehydration 20 (16.4) 5 (21.7) 15 (15.8)
Urge/fecal
incontinence
18 (14.8) 5 (21.7) 11 (11.6)
Sudden urge to
defecate
31 (25.4) 9 (39.1) 21 (22.1)
False alarm 25 (20.5) 8 (34.8) 15 (15.8)
Other 6 (4.9) 1 (4.3) 5 (5.3)
Patients could record more than one side effect. Age was not
recorded for four patients.
Table 6 Health care contacts owing to pain and/
or constipation
Number of patients (%)
(N¼198)
Primary care
Pain and/or constipation 169 (85.4)
Neither 29 (14.6)
Emergency care
Pain and/or constipation 47 (23.7)
Neither 151 (76.3)
Outpatients department
Pain and/or constipation 97 (49.0)
Neither 101 (51.0)
Overnight hospital stay
Pain and/or constipation 39 (19.7)
Neither 159 (80.3)
Other
Pain and/or constipation 28 (14.1)
Neither 170 (85.9)
Patients could record more than one health care contact.
Laxative Use in Opioid-Induced Constipation
5
 by guest on O
ctober 12, 2016
http://painm
edicine.oxfordjournals.org/
D
ow
nloaded from
 
treat pain and does not appear to be related to opioid
strength or dose. Laxatives do not appear to resolve the
problem; instead they frequently added to the patients’
burden by causing unpleasant side effects and nega-
tively impacting quality of life.
An important message for practice is that, despite constipa-
tion being a common side effect of opioid treatment, less
than half of the patients in our survey received any advice on
how to manage it. More than one in five patients said they
had to resort to removing stools by hand, giving an indication
of the severity of the constipation still endured by them, des-
pite treatment with laxatives. The use of manual evacuation
techniques was not restricted just to patients who had fre-
quently experienced constipation before starting opioids and
may have been predisposed to rectal evacuation disorders:
approximately a third of those who had not experienced
constipation previously found they also had to use one or
more such interventions. A number of patients decided to try
nonpharmacological methods (e.g., 72% altered their diet
and 20% took up exercise), but these appear not to have
worked, as almost three-quarters of patients reported that
they had used laxatives since being prescribed their current
opioid. This indicates an important role for the health care
professional, not just the patient, in managing OIC. The
range of patients who took part in the survey shows that
OIC cannot be predicted by demographics or employment
status, so each patient needs to be assessed individually.
In the absence of any formal guidance, a wide range of
laxatives was prescribed, the most common being os-
motics and stimulants. This is consistent with prescribing
patterns seen among UK respondents in a pan-European
survey of female patients with chronic idiopathic constipa-
tion [24]. OTC use was lower than we had anticipated
based on our own clinical experience and results from pre-
vious surveys [9,24]. The exception was use of OTC stimu-
lants, which was assumed to be driven by the use of senna.
Three-quarters of patients reported side effects with
their laxatives. The most common (e.g., gas and bloat-
ing) were typical of laxatives. These unwanted effects
reflect the lack of specificity in the mode of action of
laxatives, which leads to overstimulation of the GI tract.
Interestingly, younger patients reported more side ef-
fects than older patients. This is rather surprising given
that older patients are generally considered to be more
susceptible to side effects than younger patients [25].
One explanation could be that the relative minority of
younger respondents represented a group who were
more distressed by their symptoms.
Approximately half of patients reported that laxatives
interfered with their work or social life; this could tie in
with the higher incidence of side effects in younger pa-
tients and points to a socioeconomic impact of laxative
use in patients with OIC. Gas and bloating were two of
the most common factors cited by patients reporting a
substantial interference with work or social life. This sup-
ports the findings of a pan-European survey in which fe-
male patients with chronic constipation reported thatT
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relief from bloating was the aspect of their laxative that
they were least satisfied with [24].
Most patients had seen a primary care health care pro-
vider about their pain condition and/or constipation
since starting their current treatment, suggesting that a
proportion of the patients in our survey had inadequate
pain control as well as constipation. There were also a
number of secondary care visits: Approximately one-fifth
of patients had required an overnight stay in the hos-
pital, which would have had negative health care cost
implications in addition to the burden on patients.
Patients’ BFI scores provide the most compelling evi-
dence that OIC does not respond to laxatives. In fact, pa-
tients who were using laxatives recorded a higher BFI
score (i.e., they were more constipated) than those who
did not use laxatives. BFI scores were not related to opi-
oid strength, even though weak opioids are often pre-
scribed over strong opioids as they are perceived to be
“less constipating.” Coyne et al. have previously shown
that as the number of laxatives taken is increased, the
proportion of patients with an inadequate response de-
creases [9]. We found that constipation appeared to wor-
sen with increasing number of laxatives taken: 60% of
patients who had never taken laxatives had a BFI score
higher than 28.8, compared with all of those who were
taking three or more laxatives. The proportion of patients
who had a BFI score higher than 28.8 was similar to the
proportion who reported that they had needed a laxative
since starting their current opioid. Approximately one-
quarter of patients said that they had a history of consti-
pation before they started taking opioids, raising the pos-
sibility of a vulnerability to the condition. However, a post
hoc analysis showed that their BFI scores were very simi-
lar to those of the total study cohort; therefore, these pa-
tients do not appear to have influenced the results.
It might be expected that patients with a total BFI score-
higher than 28.8 would be taking higher morphine equiva-
lent doses than those with scores lower than 28.8. It was
clear, however, that constipation was not linked to opioid
strength and dose, but it was anticipated that patients
may lower their dose of opioid in an attempt to control their
constipation, an observation that correlates with previous
studies [3,7,9]. Patients with a history of constipation might
be expected to be taking lower opioid doses than those
without, but we found that the morphine equivalent doses
were generally similar between these groups. Laxative use
may be seen as an indicator that patients are taking higher
doses of opioid, but our analysis gave conflicting results
depending on whether the patients had ever taken a laxa-
tive since starting their current opioid or were currently
using laxatives. Although not formally tested, the descrip-
tive data suggested no clear relationship between increas-
ing total daily morphine equivalent dose and constipation
or laxative use; this emphasizes the need for patients to be
assessed individually.
As this was a survey, patients self-reported their symp-
toms and laxative use, so there is the potential for
inaccuracies and recall bias; this must be considered as
a limitation of these data. However, by answering an-
onymously via the internet, patients may have felt able
to give more truthful responses to sensitive questions
about bowel function than if the survey was conducted
face-to-face. It should be noted that the BFI is validated
as a tool to be used by health care professionals during
consultations with patients; it has not yet been validated
in the context of patient self-reporting.
Although patients were asked how much opioid and
laxative medication they were taking relative to the rec-
ommended daily dose, the survey did not collect infor-
mation on compliance. It would have been interesting to
see whether the negative effects of laxatives that pa-
tients described affected their dosing pattern, or
whether patients had ever reduced or missed doses of
their opioid medication to have a bowel movement (as
has been documented by several other studies [7,8,9]).
By conducting a survey, we have obtained a “real
world” perspective on prescribing, rather than a
guideline-based one. The data reflect current practice
and show that opioids are being used in a wide range
of conditions (including headache) and in combination.
These prescribing patterns emphasize the importance of
recognizing and managing OIC.
Conclusions
Use of laxatives to treat OIC is often ineffective and asso-
ciated with side effects that reflect their lack of specificity.
Instead of relieving the burden of OIC, laxatives them-
selves have a negative impact: approximately half of the
patients surveyed reported that laxatives interfere with
their work or social lives. A number of treatments that tar-
get the underlying cause of OIC are now available or in
development [22]. There is a need to develop evidence-
based treatment guidelines, which, combined with better
education for health care professionals and patients,
would be likely to shift prescribing away from multiple
courses of laxatives and toward these newer treatments.
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